J3397 HCPCS Level II code: Injection, vestronidase alfa-vjbk, 1 mg
J3397 is the HCPCS code for “Injection, vestronidase alfa-vjbk, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3397Injection, vestronidase alfa-vjbk, 1 mg
Short description: Inj., vestronidase alfa-vjbk
HCPCS · United States
Medicare details
The indicators CMS publishes with J3397 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2019
Where J3397 sits
- 1J codesDrugs administered other than orally
- 2Active code J3397Injection, vestronidase alfa-vjbk, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3397 mean?
J3397 is the HCPCS code for “Injection, vestronidase alfa-vjbk, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3397?
CMS lists J3397’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3397
All J codesJ3389Topical administration, prademagene zamikeracel, per treatmentJ3391Injection, atidarsagene autotemcel, per treatmentJ3392Injection, exagamglogene autotemcel, per treatmentJ3393Injection, betibeglogene autotemcel, per treatmentJ3394Injection, lovotibeglogene autotemcel, per treatmentJ3396Injection, verteporfin, 0.1 mgJ3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomesJ3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomesJ3400Injection, triflupromazine hcl, up to 20 mgJ3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 mlJ3402Injection, remestemcel-l-rknd, per therapeutic doseJ3403Revakinagene taroretcel-lwey, per implant